Keywords: |
cancer survival; human tissue; treatment outcome; transplantation, homologous; fludarabine; prednisone; case report; doxorubicin; cancer combination chemotherapy; cancer growth; diarrhea; drug dose reduction; cancer radiotherapy; combined modality therapy; cytarabine; rituximab; cancer staging; positron emission tomography; letter; cancer palliative therapy; carboplatin; low drug dose; computer assisted tomography; multiple cycle treatment; etoposide; antineoplastic agents, phytogenic; camptothecin; cyclophosphamide; melphalan; vincristine; autologous stem cell transplantation; hematopoietic stem cell transplantation; carmustine; ifosfamide; irinotecan; cancer regression; cord blood stem cell transplantation; nonhodgkin lymphoma; bone marrow biopsy; fluorodeoxyglucose f 18; graft versus host reaction; remission induction; single drug dose; allogeneic hematopoietic stem cell transplantation; cancer relapse; large cell lymphoma; lymphoma, large b-cell, diffuse; immunosuppressive treatment; mycophenolic acid 2 morpholinoethyl ester; transplantation, autologous; cyclosporin; lymph node biopsy; lymphadenopathy; taiwan; cyclosporine; immunosuppressive agents
|